Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

NCT04917302 is registered in ClinicalTrials.gov with China Medical University Hospital as lead sponsor.

NCT NCT04917302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04917302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
Lead sponsor
China Medical University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 13, 2020
Completion date
December 31, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia